Skip to content
Peptide research

Cortagen

Category
Brain & Cognition
Administration routes
Injectable
Regulatory status
Not FDA-approved

What it is

Cortagen is a tetrapeptide bioregulator marketed for brain aging, cognitive support, and nerve repair. The case rests on animal and mechanistic work, reduced neurological deficit and faster nerve regeneration in preclinical models, while cognitive benefit and gene reactivation in humans are speculative. There is no controlled human safety data, and it is contraindicated in pregnancy. Supply is unregulated research-grade product; not FDA-approved.

Read Full record

Studied uses & evidence

Studied uses(6)

  • Neuroprotection — reduces neurological deficit and supports brain tissue recovery after ischemic injury in animal models

    Low

    Single rat study found faster ischemic recovery and reduced oxidative stress, not independently replicated.

  • Peripheral nerve regeneration — significantly enhances nerve fiber growth rate (+27%) and conduction velocity (+40%) post-injury

    Low

    Rat studies show faster nerve fiber growth and conduction recovery, but no controlled human trials exist.

  • Epigenetic rejuvenation — induces deheterochromatinization of aged chromatin, potentially reactivating age-silenced genes

    Low

    Human leukocyte studies show chromatin decondensation with age, but no clinical rejuvenation outcome demonstrated.

Evidence limits

PRECLINICAL ONLY — No FDA-approved human clinical trials exist for Cortagen. The evidence base is limited to: (1) In vivo animal studies in rats and mice demonstrating nerve regeneration, neuroprotection from ischemia, gene expression modulation, and behavioral recovery. (2) In vitro/ex vivo studies on chromatin remodeling and epigenetic regulation. (3) Limited human observational reports from Russian clinical practice noting "pronounced therapeutic effects" on posttraumatic peripheral nerve recovery and cardiovascular/cerebrovascular parameters, but these lack the rigor of double-blind placebo-controlled trials. The overall evidence level is LOW by Western clinical standards. Published research includes Russian institutions, a Georgian chromatin study, and Italian–Russian collaboration. Independent replication by Western research groups is absent.

Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)

Cautions & risk summary

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Children under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

Risk summary(8)

Risks = level of concern: High · Moderate · Low · Theoretical

  • No human safety data from controlled clinical trials — risk profile is not well characterized

    High
  • Mild injection-site reactions (redness, swelling) reported anecdotally

    Low
  • Contraindicated in pregnancy and breastfeeding due to lack of safety data

    High
  • Patients with severe liver or kidney dysfunction should exercise caution as peptide metabolism/clearance may be altered

    Low
  • Potential for hypersensitivity or allergic reactions in susceptible individuals

    Low
  • Quality control concerns — as an unregulated research chemical, purity and composition may vary among unregulated products sold online

    High
  • Long-term effects unknown; no chronic toxicity studies published

    High
  • Epigenetic gene expression changes could theoretically have unpredictable downstream effects, though none have been documented

    Theoretical
Safety & interactions in Full record

Further reading

Read Full record

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.